Skip to main content
SpringerLink
Log in

Hochdosischemotherapie beim fortgeschrittenen Ovarialkarzinom

Nach optimaler Tumoroperation bleibt die konventionelle Chemotherapie Standard

High-dose chemotherapy in advanced ovarian cancer

Conventional chemotherapy remains the standard of care after optimal debulking surgery

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Die Hochdosischemotherapie, gefolgt von autologer Blutstammzellgabe, hat die therapeutischen Hoffnungen beim fortgeschrittenen Ovarialkarzinom nicht bestätigen können. Die kombinierte Chemotherapie mit Carboplatin und Paclitaxel über 6 Kurse in konventioneller Dosierung bleibt der Behandlungsstandard.

Abstract

High-dose chemotherapy followed by autologous blood stem cell support showed no therapeutic advantage in cases of advanced ovarian cancer. Combined chemotherapy with carboplatin and paclitaxel for six cycles using conventional dosages remains the standard therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Cure H, Battista C, Guastalla JP et al. (2004) hase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC Study. Proceedings ASCO 23: 449

    Google Scholar 

  2. Fenelly D, Schneider J, Spriggs D et al. (1995) Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of avanced ovarian cancer patients receuving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13: 1160–1166

    Google Scholar 

  3. Goncalves A, Delva R, Fabrro M et al. (2006) Post-operative sequential high-dose chemotheapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. Bone Marrow Transplant 37: 651–659

    Article  PubMed  CAS  Google Scholar 

  4. Ledermann JA, Frickhofen N, Wandt H et al. (2005) A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. J Clin Oncol [Suppl]: 23: 5006

  5. Legros M, Dauplat J, Fleury J et al. (1997) High-dose chemotherapy with hematopoetic rescue in patients with stage III to IV ovarian cancer : Long term results. J Clin Oncol 15: 1302–1308

    PubMed  CAS  Google Scholar 

  6. Wandt H, Birkmann J, Denzel T et al. (1999) Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23: 763–770

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Medizinische Klinik 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Straße 1, 90419 , Nürnberg, -

    H. Wandt

Authors
  1. H. Wandt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Wandt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wandt, H. Hochdosischemotherapie beim fortgeschrittenen Ovarialkarzinom. Onkologe 13, 425–426 (2007). https://doi.org/10.1007/s00761-006-1093-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-006-1093-8

Schlüsselwörter

Keywords

Search

Navigation